Editorial Note: Originally published on July 29, 2026, this report has been updated to incorporate the finalized regulatory language from the Centers for Medicare & Medicaid Services (CMS) regarding the 2027 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule.
The landscape of American hospital finance is undergoing a seismic shift. In a move that promises to reshape the economics of the nation’s safety-net health systems, the Centers for Medicare & Medicaid Services (CMS) has finalized its 2027 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule. At the heart of this regulation is a controversial and long-debated adjustment: a significant reduction in Medicare reimbursement rates for drugs purchased through the 340B Drug Pricing Program.
Effective January 1, 2027, Medicare will pivot from its current reimbursement rate for 340B drugs—Average Sales Price (ASP) plus 6%—to a significantly lower rate of ASP minus 28%. While this represents a slight softening from the agency’s original proposal of ASP minus 33.4%, the 32% net reduction marks a major victory for fiscal hawks who have long argued that the 340B program has strayed from its original legislative intent.
The 340B Program: A Brief Chronology
The 340B program, established by Congress in 1992, was designed as a targeted relief measure. It mandates that drug manufacturers participating in Medicaid offer outpatient drugs to eligible nonprofit and government-supported providers—such as Disproportionate Share Hospitals (DSH) and Federally Qualified Health Centers (FQHCs)—at substantial discounts.
The evolution of the program has been marked by periodic friction:
- 1992: The 340B program is signed into law to help "safety-net" providers stretch federal resources to serve low-income and uninsured populations.
- 2018: Under the first Trump administration, CMS implements a policy reducing 340B payments to ASP minus 22.5%.
- 2022: The Supreme Court strikes down the 2018 rule, ruling that CMS lacked the authority to implement the cuts without first conducting a formal hospital acquisition cost survey.
- 2026: Following a comprehensive cost acquisition survey, CMS initiates a new rulemaking process, culminating in the current 2027 policy.
- 2027: The new reimbursement schedule of ASP minus 28% takes effect, representing the most aggressive federal attempt to date to recalibrate 340B financial flows.
The Mechanics of Budget Neutrality
A critical component of this regulatory shift is the principle of "budget neutrality." Under federal law, CMS is generally prohibited from increasing aggregate spending through the OPPS. Consequently, the $4.65 billion in projected savings from the 340B reimbursement cuts cannot be returned to the U.S. Treasury; instead, it must be redistributed within the outpatient system.
To satisfy this requirement, CMS has finalized an across-the-board 7.5% increase in payments for non-drug outpatient services. This creates a "Robin Hood" effect within the hospital sector: 340B savings are effectively transferred from institutions that rely heavily on drug-related revenue to institutions that prioritize high-volume, non-drug outpatient procedures.
For the Medicare beneficiary, the impact is twofold. Patients receiving 340B-sourced medications will likely see lower out-of-pocket costs, as their 20% coinsurance will be calculated against a significantly lower base price. Conversely, patients requiring non-drug outpatient services will face higher cost-sharing obligations, as these services will now be reimbursed at the elevated 7.5% rate.
Supporting Data and Financial Implications
The financial implications of this rule are not distributed evenly. According to CMS estimates, the impact is highly dependent on a hospital’s specific business model.
Winners and Losers
The data suggests a clear divide:
- Safety-Net Hospitals: Many hospitals that serve as the primary source of care for low-income patients are expected to see a decrease in total Medicare revenue. These facilities often operate with lower margins and rely on the "spread" between the discounted 340B price and standard reimbursement to fund wraparound services, such as community clinics, transportation assistance, and pharmacy programs for the indigent.
- For-Profit and Non-340B Hospitals: Facilities that do not participate in the 340B program, or those with lower reliance on drug-based margins, stand to benefit from the 7.5% bump in non-drug outpatient reimbursements. For-profit hospital chains, which often maintain higher operating margins, are positioned to see a net increase in revenue as a result of the redistribution.
CMS has provided narrow exemptions to cushion the impact on the most vulnerable providers. Rural Sole Community Hospitals (SCHs), children’s hospitals, and PPS-exempt cancer hospitals are excluded from the reimbursement cuts. Crucially, Critical Access Hospitals (CAHs)—which constitute the majority of rural hospitals—remain unaffected as they are not reimbursed under the OPPS.
Official Responses and Industry Friction
The reaction to the final rule has been polarized, reflecting a long-standing tension between pharmaceutical interests, hospital advocacy groups, and federal regulators.
The CMS Perspective:
CMS officials have defended the rule as a necessary "correction." By aligning reimbursement more closely with the actual acquisition costs identified in the 2026 survey, the agency argues it is preventing hospitals from generating excess revenue from a program meant for charity. They assert that the rule will increase transparency and stabilize the long-term viability of the OPPS.
The Hospital Industry Response:
The American Hospital Association (AHA) and other advocacy groups have expressed profound concern. They argue that the "savings" the government is reclaiming are, in fact, essential funding for community health initiatives. Critics of the rule warn that by cutting these revenues, the government is inadvertently forcing safety-net hospitals to reduce services, close specialty clinics, or limit access to expensive, life-saving medications for the very patients the 340B program was intended to protect.
The Pharmaceutical Industry Position:
Many pharmaceutical companies have long lobbied for stricter 340B oversight, arguing that the program has incentivized hospitals to aggressively acquire physician practices to inflate the number of 340B-eligible prescriptions. They maintain that the program has expanded far beyond its original scope and that the CMS rule is a reasonable step toward curbing "program creep."
Emerging Legal and Legislative Challenges
The 2027 rule does not exist in a vacuum. It is part of a broader, high-stakes battle over the future of federal drug pricing.
The Rebate Model Controversy
Simultaneously, the industry is grappling with the "rebate model." Several pharmaceutical manufacturers have attempted to transition from upfront discounts to a post-sale rebate system. This would fundamentally change the cash flow for hospitals, requiring them to purchase drugs at full price and wait for reimbursement—a process that would place immense strain on the liquidity of smaller hospitals.
While the Trump administration’s attempt to formalize a 340B Rebate Model Pilot Program was stalled by litigation, HHS announced a revised version in July 2026. This, too, has been met with immediate legal challenges, setting the stage for a protracted court battle that will likely define the legal boundaries of the 340B program for years to come.
Legislative Transparency
At the congressional level, there is growing bipartisan interest in "340B transparency." Several proposed bills would require hospitals to publicly report their 340B savings and provide detailed accounting of how those funds are reinvested into patient care. Proponents of these measures argue that if 340B is truly a safety-net program, then hospitals should be willing to provide the data to prove it.
Conclusion: The Path Ahead
The 2027 Medicare OPPS rule is more than just a change in accounting; it is a fundamental shift in the government’s relationship with the healthcare safety net. By forcing a reallocation of billions of dollars, CMS has signaled that the status quo of the 340B program is no longer sustainable in the eyes of federal regulators.
For the healthcare industry, the next twelve months will be defined by adaptation. Hospitals will be forced to conduct rigorous internal audits to determine their exposure to these cuts and likely re-evaluate their reliance on pharmacy-based revenue. As the January 1 implementation date approaches, the focus will remain on whether these cuts will improve the fairness of Medicare spending or whether they will inadvertently create a new crisis for the nation’s most vulnerable patients.
The legal challenges currently winding through the courts suggest that the final word on 340B has yet to be spoken. However, for now, the 2027 rule stands as the new reality for American medicine.
About the Author
